» Authors » Michael N Petrus

Michael N Petrus

Explore the profile of Michael N Petrus including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 407
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Daenthanasanmak A, Bamford R, Yoshioka M, Yang S, Homan P, Karim B, et al.
Blood Adv . 2022 Jan; 6(7):2346-2360. PMID: 35030628
Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell lymphoproliferative malignancy caused by human T-cell leukemia virus type 1 (HTLV-1). ATL is an orphan disease with no curative drug treatment regimens...
2.
Ishio T, Kumar S, Shimono J, Daenthanasanmak A, Dubois S, Lin Y, et al.
Blood . 2021 Nov; 139(10):1541-1556. PMID: 34818414
Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy with a poor prognosis with current therapy. Here we report genome-wide CRISPR-Cas9 screening of ATLL models, which identified CDK6, CCND2, BATF3,...
3.
Bellon M, Bialuk I, Galli V, Bai X, Farre L, Bittencourt A, et al.
Mol Cancer . 2021 Jun; 20(1):86. PMID: 34092254
Background: Human T cell Leukemia virus type 1 (HTLV-I) is etiologically linked to adult T cell leukemia/lymphoma (ATL) and an inflammatory neurodegenerative disease called HTLV-I-associated myelopathy or tropical spastic paraparesis...
4.
Dubois S, Miljkovic M, Fleisher T, Pittaluga S, Hsu-Albert J, Bryant B, et al.
J Immunother Cancer . 2021 Apr; 9(4). PMID: 33883258
Background: Full application of cytokines as oncoimmunotherapeutics requires identification of optimal regimens. Our initial effort with intravenous bolus recombinant human interleukin-15 (rhIL-15) was limited by postinfusional reactions. Subcutaneous injection and...
5.
Wang H, Wei W, Zhang J, Song Z, Li Y, Xiao W, et al.
Leukemia . 2020 Nov; 35(7):1976-1989. PMID: 33184494
Aberrant activation of NF-κB is the most striking oncogenic mechanism in B-cell lymphoma; however, its role in anaplastic large cell lymphomas (ALCL) has not been fully established and its activation...
6.
Song Z, Wei W, Xiao W, Al-Saleem E, Nejati R, Chen L, et al.
Proc Natl Acad Sci U S A . 2020 Nov; 117(46):28980-28991. PMID: 33139544
More than 70% of Epstein-Barr virus (EBV)-negative Hodgkin lymphoma (HL) cases display inactivation of TNFAIP3 (A20), a ubiquitin-editing protein that regulates nonproteolytic protein ubiquitination, indicating the significance of protein ubiquitination...
7.
Daenthanasanmak A, Lin Y, Zhang M, Bryant B, Petrus M, Bamford R, et al.
Transl Oncol . 2020 Oct; 14(1):100913. PMID: 33129109
Adult T-cell leukemia (ATL) is an aggressive T-cell lymphoproliferative malignancy of regulatory T lymphocytes (Tregs), caused by human T-cell lymphotropic virus 1 (HTLV-1). Interleukin 2 receptor alpha (IL-2Rα) is expressed...
8.
Volko J, Kenesei A, Zhang M, Varnai P, Mocsar G, Petrus M, et al.
Proc Natl Acad Sci U S A . 2019 Oct; 116(42):21120-21130. PMID: 31570576
Interleukin-2 (IL-2) and IL-15 play pivotal roles in T cell activation, apoptosis, and survival, and are implicated in leukemias and autoimmune diseases. Their heterotrimeric receptors share their β- and γ-chains,...
9.
Nakagawa M, Shaffer 3rd A, Ceribelli M, Zhang M, Wright G, Huang D, et al.
Cancer Cell . 2018 Jul; 34(2):286-297.e10. PMID: 30057145
Adult T cell leukemia/lymphoma (ATLL) is a frequently incurable disease associated with the human lymphotropic virus type I (HTLV-I). RNAi screening of ATLL lines revealed that their proliferation depends on...
10.
Perera L, Zhang M, Nakagawa M, Petrus M, Maeda M, Kadin M, et al.
Am J Hematol . 2017 May; 92(9):892-901. PMID: 28543380
With the emerging success of treating CD19 expressing B cell malignancies with ex vivo modified, autologous T cells that express CD19-directed chimeric antigen receptors (CAR), there is intense interest in...